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Great efforts have been made to limit the transmission of carbapenemase‑producing 
Enterobacteriaceae (CPE), however, the intestinal reservoir of these strains and its modulation 
by various antibiotics remain largely unexplored. Our aim was to assess the effects of antibiotic 
administration (ampicillin, ceftazidime, ciprofloxacin) on the establishment and elimination of 
intestinal colonization with a CTX‑M‑15 ESBL and OXA‑162 carbapenemase producing Klebsiella 
pneumoniae ST15 (KP5825) in a murine (C57BL/6 male mice) model. Whole genome sequencing of 
KP5825 strain was performed on an Illumina MiSeq platform. Conjugation assays were carried out 
by broth mating method. In colonization experiments, 5 ×  106 CFU of KP5825 was administered 
to the animals by orogastric gavage, and antibiotics were administered in their drinking water for 
two weeks and were changed every day. The gut colonization rates with KP5825 were assessed by 
cultivation and qPCR. In each of the stool samples, the gene copy number of blaOXA‑162 and blaCTX‑M‑15 
were determined by qPCR. Antibiotic concentrations in the stool were determined by high pressure 
liquid chromatography and a bioanalytical method. The KP5825 contained four different plasmid 
replicon types, namely IncFII(K), IncL, IncFIB and ColpVC. IncL (containing the blaOXA‑162 resistance 
gene within a Tn1991.2 genetic element) and IncFII(K) (containing the blaCTX‑M‑15 resistance gene) 
plasmids were successfully conjugated. During ampicillin and ceftazidime treatments, colonization 
rate of KP5825 increased, while, ciprofloxacin treatments in both concentrations (0.1 g/L and 0.5 g/L) 
led to significantly decreased colonization rates. The gene copy number blaOXA‑162 correlated with K. 
pneumoniae in vivo, while a major elevation was observed in the copy number of blaCTX‑M‑15 from the 
first day to the fifteenth day in the 0.5 g/L dose ceftazidime treatment group. Our results demonstrate 
that commonly used antibiotics may have diverse impacts on the colonization rates of intestinally‑
carried CPE, in addition to affecting the gene copy number of their resistance genes, thus facilitating 
their stable persistance and dissemination.
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CPE  Carbapenemase-producing Enterobacteriaceae
CRKP  Carbapenem-resistant Klebisella pneumoniae
ESBL  Extended-spectrum β-lactamase
HGT  Horizontal gene transfer
HPLC  High-performance liquid chromatography
KP5825  K. pneumoniae Strain no. 5825
LoD  Limit of detection
LB  Luria -Bertani
MIC  Minimum inhibitory concentration
MDR  Multidrug resistant
NA  Not available
ST  Sequence type
Multidrug-resistant (MDR) Gram-negative bacteria have emerged as a major public health threat. Extended-
spectrum β-lactamase (ESBL)-producing Enterobacteriaceae have disseminated worldwide and have become a 
serious concern for clinicians, due to limited therapeutic options, both in community-acquired and nosocomial 
 infections1. In the last decade, CTX-M-type ESBLs have replaced TEM- and SHV-types among clinical Entero-
bacteriaceae  isolates2. The explosive dissemination of CTX-M-type β-lactamases around the world has been 
referred to as the “CTX-M pandemic”, associated with their increasing description around the  globe3, and their 
prevalence rates may vary among different members of the Enterobacteriaceae family; nevertheless, they are most 
common in species, such as Klebsiella pneumoniae and Escherichia coli4. The increasing prevalence of infections 
caused by MDR Gram-negative bacteria (especially ESBL-producers) was accompanied with the rise in the use 
of carbapenems for the treatment of these  infections5. Subsequently, this has further enhanced the emergence 
and dissemination of carbapenemase-producing Enterobacteriaceae (CPE). Although resistance rates to carbap-
enems remain low in some parts of Europe, the developments in southern and southeastern Europe (which were 
previously characterized by an unrestricted use of these life-saving drugs) is  concerning6.
CPE infections are associated with high morbidity and mortality, particularly in vulnerable patient popula-
tions, including infants, children and the elderly, hospitalized patients, immuncommpromised patients, as well 
as the critically ill. The major driving force in the uncontrolled dissemination of these strains is their ability to 
survive and spread rapidly in healthcare environments; in fact, carbapenemase-production is usually linked 
to successful MDR clones, commonly associated with nosocomial  infections7,8. The carbapenemase genes in 
Enterobacteriaceae have been shown to be associated with mobile genetic elements including plasmids or trans-
posons, allowing for the transfer among different members of the family. OXA-48-like carbapenemases are one 
of the most common carbapenemases (with increasing prevalence in Europe, although wide-ranging differ-
ences in their geographic distribution may be observed) in Enterobacteriaceae, and they are continuously being 
introduced into regions of non-endemicity, where they may be responsible for nosocomial  outbreaks6,9. While 
K. pneumoniae is the main reservoir of blaOXA-48, the number of studies reporting cases due to other blaOXA-48 
producing Enterobacteriaceae species is increasing  worldwide8,10,11.
Due to the high prevalence and pervasiveness of blaOXA-48-like carbapenemases in community-associated and 
nosocomial Gram-negative bacteria, limiting the additional spread of pathogens producing these enzymes is 
a difficult  task11,12. BlaOXA-48-like/blaOXA-48 carbapenemases are found on plasmids that have a high propensity to 
disseminate among various bacterial species via horizontal gene transfer (HGT)9. It is not uncommon to detect 
different bacteria containing identical plasmids harboring blaOXA-48, obtained from the same patient, both as 
colonizers or as causative agents of  infections13. OXA-48 is associated with different Tn1999 transposon vari-
ants and located mainly as the only antibiotic resistance gene on the conjugative IncL (IncL/M) replicon type 
 plasmids14,15. The occurrence of pOXA-48a-like IncL plasmids were described in many Gram-negative bacteria, 
including Citrobacter freundii, E. coli, Enterobacter cloacae, K. pneumoniae, K. oxytoca and Raoultella planti-
cola16,17. Some high-risk clones (e.g., ST11, ST15, ST101 and ST307 for K. pneumoniae, and ST38 and ST410 for 
E. coli) have been associated with the global dispersal of many OXA-type carbapenemases (OXA-48, OXA-181, 
OXA-232 and OXA-204)13,18–20. OXA-162—which is also a member of the OXA-48-like carbapenemases—has 
been observed in different gut bacteria, reported from Turkey, Germany, Greece and Hungary until  now10,21–23.
Enterobacteriaceae are inhabitants of human gut microbiota, and feacal carriers may represent an important 
reservoir for person-to-person transmission and dissemination of bacteria. Furthermore, gut colonization by 
MDR bacteria has been associated with a high risk of developing subsequent clinical infection associated with 
increased  mortality7,24. Therefore, active surveillance is a key part in preventing the spread of such strains. Efforts 
to limit the transmission of carbapenemase-producing K. pneumoniae strains focus on basic and enhanced 
infection control measures, while the importance of the intestinal reservoir of these strains and its modulation 
by various antibiotics remain largely  unexplored25. Administration of antibiotics is a known risk factor for the 
development of resistance, however its role in colonization is still unclear. In this study, our aim was to assess 
the effects of antibiotic administration on the establishment and elimination of intestinal colonization with a 
CTX-M-15 ESBL and OXA-162 carbapenemase co-producing K. pneumoniae in a murine model, followed by 
administration of ampicillin, ceftazidime or ciprofloxacin (Fig. 1).
Results
Based on the whole genome sequencing the KP5825 strain harboured blaCTX-M-15 ESBL and the blaOXA-162 carbap-
enemase, as well as other antibiotic resistance-determinants for β-lactam resistance (blaSHV-28 and blaOXA-1). The 
KP5825 isolate harboured several chromosomal nucleotid mutations resulted in GyrA amino acid alterations in 
position Ser83Phe, Asp87Ala and Asn645His and in ParC in position Ser80Ile and Pro402Ala, furthermore the 
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isolate also carried the plasmid-borne aac(6′)-Ib-cr fluoroquinolone resistance determinant. The isolate carried 
resistance-determinants for aminoglycoside resistance (aac(3)-IIa, aph(3′)-Ia and aac(6′)Ib-cr as well. In addition, 
four different plasmid replicon types, namely IncFII(K), IncL, IncFIB and ColpVC were detected in the KP5825. 
The IncL and IncFII plasmids were successfully conjugated, and the IncL plasmid contained only the blaOXA-162 
resistance gene within a Tn1991.2 genetic element, while the IncF(II)K contained the blaCTX-M-15 resistance gene.
The KP5825 showed high level resistance against the beta-lactam and fluoroquinolone antibiotics based on 
MIC values determined in the broth microdilution assay. The broth mating procedure-based in vitro conjuga-
tion assay performed was successful, and the conjugated E. coli J53 harbouring the pOXA-162 showed increased 
resistance in case of ertapenem and meropenem and in case of E. coli J53 harbouring pCTX-M-15, resistance 
to cephalosporins (ceftazidime, cefotaxime) was detected. The characteristics of KP5825 and the conjugated E. 
coli J53 strains are shown in Table 1.
In the colonization studies with 6–8 week-old C57BL/6 male mice the antibiotics were administered in their 
drinking water for two weeks. The concentration of antibiotics in mouse stool was assessed with high pressure 
liquid chromatography (HPLC) on the 1st and 15th day after KP5825 colonization. The ampicillin concentra-
tion in the stool samples in Amp_0.5 group on the first day was 720.2 ± 247.0 µg/g (average ± SD), while on the 
fifteenth day 739.3 ± 219.4 µg/g. The average ciprofloxacin concentration in the Cip_0.1 group was 17.2 ± 5.96 µg/g 
on the first day, and 20.7 ± 4.97 µg/g on the fifteenth day; and in Cip_0.5 group, it was 203.8 ± 46.0 µg/g on the 
first day and 244.8 ± 61.9 µg/g on fifteenth day. Ceftazidime was undetecable from mice stool samples.
The colonization was performed with the KP5825 strain administered by orogastric gavage and the coloniza-
tion rate of mice with CTX-M-15 ESBL- and OXA-162 carbapenemase-producing KP5825 was quantified by 
both a conventional culture analysis method and the qPCR technique, in order to simultaneously determine 
the absolute and relative colonization rates with the tested isolate. The effect of different treatment regimens 
on colonization with KP5825 are shown in Fig. 1A,B. The densities of KP5825 detected in feces were assayed 
on the 3rd, 6th, 9th, 12th and 15th days. If KP5825 organisms were not detected in the stool, the lower limit of 
detection (~ 2.3  log10 CFU/g) was assigned. In case of all observation periods of ceftazidime treatments, the rate 
of KP5825 colonies were the highest, while on the other hand, during ciprofloxacin treatments they were the 
lowest (Fig. 2A). During ampicillin (Amp_0.5) and ceftazidime treatments (Caz_0.1 and Caz_0.5), the absolute 
Figure 1.  The colonization protocol used in our experiments.
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colonization rate of the carbapenem-resistant KP5825 slightly increased. Upon treatment with ampicillin, a 
moderate increase of K. pneumoniae cell count was detected. In contrast, during ciprofloxacin treatments in both 
concentrations (Cip_0.1 and Cip_0.5) and in the control group, the colonization rates have decreased signifi-
cantly. The most extensive decrease in colonization rate was observed in the group treated with the lower dose of 
ciprofloxacin (Cip_0.1). These alterations are the most unexpected as the present carbapenemase-producing K. 
pneumoniae shows high level resistance to fluoroquinolones. These results were consequent with qPCR results 
by observing the  log10 fold change of rpoB1 housekeeping gene designed for KP5825. The relative colonization 
rate of KP5825 between the first and fifteenth day of colonization showed also differences between antibiotic 
treatments. In Caz_0.1 group the colonization rate of carbapenem-resistant KP5825 slightly increased, while on 
the other hand treatment with ampicillin resulted in a moderate increase of KP5825. An extensive decrease in 
colonization rate was observed in the groups treated ciprofloxacin (Cip_0.1, Cip_0.5) (Fig. 2B).
The effect of antibiotic-treatment regiments on blaCTX-M-15 and blaOXA-162 genes’ copy number in the gut was 
determined by qPCR from each the stool sample and results were calculated as the fold change of gene normalized 
to the rpoB1 reference gene and relative to the control mice. The relative copy number of the ESBL blaCTX-M-15 
and the carbapenemase blaOXA-162 were determined and these results were correlated to the rpoB1 housekeeping 
gene of KP5825 on the first and on the fifteenth days from the feces of each mouse used in the experiment (Fig. 3). 
The relative copy number did not change for blaOXA-162 during the observed period in any treatment group. In 
contrast, a major elevation was observed from the first day to the fifteenth day in the treatment group with the 
Caz_0.5 treatment yielding 2 and 400-fold absolute gene copy number increase of the blaCTX-M-15 gene. At the 
same time, the relative copy number of the blaCTX-M-15 gene (which was controlled with the rate of the rpoB gene) 
also increased significantly (p < 0.05) from 2- to 5-times relative to the control in the Caz_0.5 treatment group 
(Fig. 3). Nevertheless, only the original CTX-M-15 and OXA-162-producing K. pneumoniae isolate could be 
reisolated from various feaces samples from mice during the experiment using the selective CHROMagar plates. 
We could not isolate other ESBL or carbapenenamse-producing bacteria on the appropriate selective culture 
media, except the original KP5825.
Discussion
Klebsiella pneumoniae is a prevalent and dangerous cause of hospital-associated infections, especially in  ICUs24,25. 
Because of their global spread, high mortality and very limited therapeutic options, carbapenem-resistant K. 
pneumoniae (CRKP) was declared a major public health threat, rated as priority 1, critical pathogen by the World 
Health  Organization26–28. Patients with intestinal carriage of CRKP upon admission may act as  reservoirs29; 
moreover, gastrointestinal colonization with MDR K. pneumoniae increases the risk of subsequent infections 
and  mortality29,30. Colonization with a carbapenem-resistant Klebsiella has been highlighted as a hallmark of a 
subsequent extraintestinal infection by these pathogens; therefore, the identification of patients whom are posi-
tive for CRKP-colonization may be an important step to introduce infection control interventions and to save 
patients from developing an  infection31.
Our experiments aimed to investigate the effects of various antibiotic treatments on the gastrointestinal 
colonization, gene dynamics and role in the resistome of the high-risk clone K. pneumoniae ST15, producing the 
Table 1.  Features of KP5825 and the transconjugated E. coli J53 strains. MIC: minimum inhibitory 
concentrations; NA: not applicable.
Strains
KP5825 E. coli J53
E. coli J53 Transconjugant-5825/1 
pCTX-M-15
E. coli J53 Transconjugant-5825/2 
pOXA-162
Plasmid replicon types IncF(I)B, IncF(II)K, ColpVC, IncL NA IncF(II)K IncL
Beta-lactamases
NA blaCTX-M-15 blaOXA-162Chromosomal blaSHV-28
On mobile genetic elements blaOXA-1, blaOXA-162, blaCTX-M-15
Mobile genetic elements Class I, Tn1999.2, NA Class I Tn1999.2
Quinolone resistance determinants
NA aac(6′)Ib-crChromosomal
gyrA (S83F, D87A, N645H)
parC (S80I, P402A)
On mobile genetic elements aac(6′)Ib-cr
Other resistance genes aac(3)-IIa, aph(3′)Ia NA
MIC (mg/L)
Ampicillin  > 32 4  > 32  > 32
Ceftazidime  > 32 0.25  > 32 0.25
Cefotaxime  > 32 0.125  > 32 0.25
Ertapenem  > 32  < 0.0625  < 0.0625 0.25
Imipenem 16 0.5 0.5 0.5
Meropenem  > 32  < 0.0625  < 0.0625 0.125
Ciprofloxacin  > 32  < 0.0625  < 0.0625  < 0.0625
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Figure 2.  (A) Effect of various antibiotic administration on the establishment of intestinal colonization with 
KP5825 by orogastric gavage on day 0 (n = 7 mice per antibiotic treatment group). Densities of KP5825 are 
shown on 3rd, 6th, 9th, 12th and 15th days after colonization. The limit of detection (LoD) (~ 2.3  log10 CFU/g) 
was assigned. Colums represent median values. (B) Changes in the relative colonization rate by KP5825 in the 
antibiotic-treated groups and in the control group. The  log10 fold change of rpoB1 housekeeping gene show the 
relative colonization rate between the first and fifteenth day of the colonization with the different treatment.
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CTX-M-15 and OXA-162 β-lactamases, focusing on the major problem of the emergence and spread of ESBL and 
carbepenemase genes. In case of OXA-162, the host plasmid IncL and in case of CTX-M-15, the host plasmid 
IncFII of the high risk clone K. pneumoniae play an important role in its international dissemination. In our 
experiment, both plasmids were shown to be conjugable. OXA-48-like enzymes itselves hydrolyze carbapenems 
to a lesser extent, as we also observed, however their co-occurrence with other β-lactam resistance mechanisms, 
such as membrane impermeability, may result in high-level carbapenem-resistance9–11.
Three antibiotics were included in our study, namely ampicillin, ceftazidime (representatives of β-lactams) 
and ciprofloxacin. Ampicillin and its derivates (i.e. the aminopenicillins) and ciprofloxacin (a member of the 
fluoroquinolones) are still one the most widely used drugs in the community, therefore, the assessment of their 
effect on the gut resistome is of utmost  importance32. Ceftazidime has been recently sidelined in therapy, due to 
its availability and the emergence of ESBLs worldwide. Nevertheless, the introduction of ceftazidime and avi-
bactam, a novel cephalosporin/β-lactamase inhibitor combination into the clinical practice—especially for the 
treatment of OXA-48-type (Class D) carbapenemase producing MDR Gram-negative organisms has provided 
renewed relevance to this  drug33,34. Results of our experiments have shown that the studied antibiotic treatment 
regiments affected the resistome of mice in different ways.
Previous antibiotic therapy is an independent risk factor for colonization with ESBLproducing Enterobacte-
riaceae as demonstrated several  studies35,36. During our studies, ampicillin pre-treatment was used (for a duration 
of 14 days) to maintain and promote the colonization of KP5825 in all treatment groups, which was done to 
model the natural colonization of the host with the microorganism. The rationale behind this was that—based 
on literature findings—gastro-intestinal colonization with K. pneumoniae is difficult to establish in mice via 
gavage treatment and that antibiotic (ampicillin) pre-treatment has been noted to play a role in disrupting the 
microbiota of the desired host to allow for the colonization of K. pneumoniae37,38.
There are controversial data regarding the effects of beta-lactam treatment on the gastrointestinal colonization 
with multi-drug reistant organisms. Several authors have noted that exposure to various β-lactam antibiotics 
allow for the colonization by ESBLs (an ST131 E. coli strain was used in the experiments), regardless of nega-
tively affecting (clindamycin) the members of the Bacteroidales order or not (cefuroxime and dicloxacillin)39. 
Conversely, others reported that the treatment with cephalosporins at the ICU did not increase the acquisition 
rate of carbapenem-resistant Enterobacteriaceae40. In our study, as a consequence of the treatment with β-lactam 
antibiotics, both the colonization rate and—independently from this—the gene copy number of blaCTX-M-15 both 
increased. Nevertheless, the copy number of blaOXA-162 correlated with the colonization rate of KP5825. In the 
case of blaCTX-M-15 located on IncF(II)K plasmid, a higher gene copy number was detected in mice stool samples 
after cephalosporin treatment, thus indicating a shift in resistome. The measurement of the replicon’ copy num-
ber could have additionally provided valuable information on the underlying reasion for the observed increase, 
however, this experiment was unfortunately not performed. Given that the CTX-15-producing transconjugant 
could not be isolated from stool samples, highlights that either recipient Enterobacteriales was not detectable 
Figure 3.  The relative copy number of the blaCTX-M-15 and blaOXA-162 genes from the feces of individual mice 
after the different antibiotic-treatment regiments on the first and fifteenth days after colonization with KP5825.
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(or culturable) in feces of mice or the copy number of blaCTX-M-15 resistance genes was increased only in the host 
cells. Thus, it may also be assumed that the blaCTX-M-15 gene may have been transferred to non-culturable bacte-
ria. However, this does not change the fact that blaCTX-M-15 gene was present in higher levels and the plasmid is 
capable of conjugation in present of susceptible recipient bacterium.
The fact that ciprofloxacin reduced the colonization rate in our experiments is particularly interesting, espe-
cially in light of the fact that the colonizing K. pneumoniae strain itself had high-level fluoroquinolone resist-
ance as it had both chromosomal and plasmid-mediated quinolone resistance determinants. Regardless, our 
carbapenem-resistant K. pneumoniae isolate disappeared or its load has significantly decreased in the feces 
of ciprofloxacin treated mice. These findings support earlier studies where ciprofloxacin did not increase the 
abundance of antibiotic resistance genes-carrying plasmids and failed to promote colonization with MDR Gram-
negative  bacteria37,41. A potential explanation involves the limited antimicrobial effects of ciprofloxacin on the 
anaerobic intestinal  microbiota42.
Based on the results of our experiments, it may be assumed that the differences in the colonization effects of 
the tested antibiotics are mainly rooted in their structre-activity relationships and biological targets, rather then 
the doses in which they were applied (there were no difference between different doses of the same antibiotic). 
These results highlights the fact that the that timing of the antimicrobial adiministration relative to CPE exposure 
is also an important parameter to consider in providing ecological space for the implantation and expansion of 
the MDR strain.
Conclusions
In summary, our results have shown that in the presence of β-lactam antibiotics, the amount of the high-risk 
clone of K. pneumoniae showed an increase in the absolute and relative colonization rate, as well as gene copy 
number of blaCTX-M-15 on the IncF(II) conjugative plasmid. In contrast, gene copy of blaOXA-162—which was also 
conjugative in vitro on IncL plasmid—correlated with K. pneumoniae cell count in vivo. Increases in the degree of 
colonization in the presence of antibiotics has been described by previous studies, however, a clone-independent 
change in the copy number of blaCTX-M-15 resistance genes in vivo has not been previously described. In contrast, a 
parallel decrease in both the clone and the resistance genes was observed after the treatment of fluoroquinolones. 
This has already been observed by others, but contrasting observations have also been published. Gastrointestinal 
colonization of MDR bacteria poses a serious clinical problem, both in community-based and nosocomial set-
tings, and in our study we demonstrated a diverse influence of commonly administered antibiotics (ampicillin, 
ceftazidime, ciprofloxacin) on intestinally carried multidrug-resistant K. pneumoniae.
Methods
Bacterial strains. K. pneumoniae ST15 (KP5825) was obtained from National Public Health Centre (Buda-
pest, Hungary)23. Azide-resistant E. coli J53 was used in the conjugation assays.
Antibacterial susceptibility testing. Antibacterial susceptibility testing was performed by the broth 
microdilution method according to the EUCAST guidelines v.9.0 (www. eucast. org)43. Incubation was per-
formed at 35 °C for 16–20 h and minimum inhibitory concentrations (MICs) were determined visually. E. coli 
ATCC 25922 was used as control strain.
Conjugation assay. Conjugation assays were carried out by broth mating procedure in Lurian-Bertani 
(LB) broth (Sigma-Aldrich, USA) with the KP5825 isolate as donor and the E. coli J53 azide resistant strain as 
 recipient43. Overnight cultures of donor and recipient strains grown in LB broth were added to 8 mL fresh LB 
broth at a donor-recipient ratio of 1:1 (300 μL of cultures each), and incubated for 4 h at 37 °C. The mixed cul-
tures were centrifuged and the supernatant was removed in order to get rid of the antibiotics, to avoid the inhibi-
tory effect against E. coli J53. The pellet was re-suspended in fresh culture and plated onto a LB-agar containing 
100 μg/mL azide (Sigma-Aldrich) and 0.1 μg/mL of cefotaxime (Sigma-Aldrich) and/or 0.1 μg/mL of ertapenem 
(Sigma-Aldrich)44. Colonies growing on the selective agar plates and again on subculture agar were subjected to 
confirmatory tests of ESBLs and carbapenemase by CTX-M Multi and Carba 5 immunochromatographic assays 
(NG Biotech, Guipry, France).
Mouse model of in vivo colonization with KP5825. All experiments were carried out using 6–8 week-
old C57BL/6 male mice weighted 24–26 g (Jackson Laboratory, Bar Harbor, Maine, USA) and housed in sterile 
cages with irradiated food and acidified water. Each group contained seven mice. For experiments involving 
antibiotic treatment, 0.5 g/L of ampicillin (Sandoz GmbH) was administered to animals in the drinking water 
for fourteen days and changed every day. For colonization experiments, 5 ×  106 CFU of K. pneumoniae KP5825 
was administered by orogastric gavage in a 200 μl volume on the fourteenth and fifteenth day of ampicillin pre-
treatment. After the oral colonization with KP5825 the following antibiotics—0.5 g/L ampicillin (Amp_0.5), 
0.1 g/L ceftazidime (GlaxoSmithKline) (Caz_0.1), 0.5 g/L ceftazidime (Caz_0.5), 0.1 g/L ciprofloxacin (Bayer 
AG) (Cip_0.1) and 0.5 g/L ciprofloxacin (Cip_0.5)—were further administered to the animals in the drinking 
water for two weeks and changed every day (Fig. 1).
Mice were single-housed at the time of colonization experiment. Animals were maintained in a specific 
pathogen-free facility at Institute of Medical Microbiology, Semmelweis University. All mouse handling, cage 
changes and feacal pellet collection were performed in a biosafety level 2 (BSL-2) facility, with personnel wearing 
sterile gowns, masks and gloves.
8
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6335  | https://doi.org/10.1038/s41598-021-85766-6
www.nature.com/scientificreports/
Sequencing. Genomic DNA from KP5825 was isolated by NucleoSpin Microbial DNA Kit (Macherey 
Nagel), and plasmid DNA was isolated by NucleoSpin Plasmid DNA Kit (Macherey Nagel) according to the 
manufacturer’s instructions. The quality and quantity of isolated DNA was assessed by measurements using a 
Qubit 4.0 fluorometer (Invitrogen, Waltham, USA) and Tapestation 4150 systems (Agilent, Santa Clara, USA). 
The NGS libraries were prepared using the Nextera DNA Flex Library Prep Kit (Illumina, Eindhoven, The Neth-
erlands) with Nextera DNA CD  Indexes45. The NGS libraries were sequenced on an Illumina MiSeq instrument 
using the MiSeq Reagent Kit v2 using paired end 250 bp reads at the Genomics Resource Center at the Biomi 
Ltd. The fastq files were imported directly from Illumina BaseSpace to the BioNumerics version 7.6 software’s 
(Applied Maths NV, Belgium) cloud-based calculation  engine45. De novo sequence assemblies were made with 
the SPAdes de novo genome assembler (version 3.7.1).
Accession numbers, data deposition. The genomic assembly of the OXA-162 and CTX-M-15 produc-
ing K. pneumoniae KP5825 have been deposited at European Nucleotide Archive at study PRJEB38863. The 
assembly of the plasmid containing the OXA-162 submitted under ERZ1461529 accession number and the plas-
mid containing the CTX-M-15 submitted under ERZ1462751 accession number to the European Nucleotide 
Archive.
Determination of the antibiotic concentrations in the fecal samples of mice. The concentrations 
of antibiotics in the stool samples of each mice were determined by HPLC at two different time points: on the 
first and fifteenth day after colonization with KP5825. For the determination of ampicillin, mouse fecal pellets 
were extracted with acetonitrile–water mixture after homogenization and derivatized with formaldehyde. The 
fluorescent derivative was separated on a Phenomenex Kinetex EVO C18 column and detected at λex = 346 nm 
and λem = 422 nm wavelenghts. Ciprofloxacin was extracted from mouse faeces with 0.1 M phosphoric acid. The 
sample extract was separated on the same column and detected at λex = 310 nm and λem = 445 nm wavelenghts 
using fluorescent detection. Ceftazidime was extracted with water and separated on an Agilent Polaris 3 C18-
Ether column followed by UV detection at 261 nm.
Assessment of the colonization rate with KP5825 by cultivation during different antibiotic 
treatments. To quantify the burden of KP5825, fresh stool samples were collected on the 3rd, 6th, 9th, 12th 
and 15th days after the colonization with KP5825. Fresh stool specimens were used for the quantitative culture 
of KP5825. Serially diluted aliquots were inoculated onto a selective CHROMagar (Mast Diagnostika, Reinfeld, 
Germany) containing 0.1 μg/mL cefotaxime. Plates were incubated at 37 °C for 48 h and the CFU per gram 
of stool was calculated. The color and morphological characteristics of the colonies grown were assessed on 
CHROMagar (Mast Diagnostika) after 24 h and 48 h of incubation in ambient air at 35 °C.
Assessment of the colonization rate with KP5825 and copy number of  blaCTX‑M‑15 and  blaOXA‑162 
by qPCR assay during different antibiotic treatments. Genomic DNA of KP5825 was extracted by 
QiaAmp Power fecal kit (QIAGEN, Venlo, NL) strictly based on manufacturer protocols. Oligonucleotid prim-
ers and FAM (fluorescein amidite)- and VIC (2′-chloro-7′phenyl-1,4-dichloro-6-carboxy-fluorescein)-labelled 
probes were designed by Primer Express 3.0 software (Table 2). The qPCR was carried out in a Step One Real-
Time PCR System (Applied BioSystems, Thermo Fisher Scientific) in default setting. The copy number of resist-
ance gene results were evaluated using the  2−ΔΔCt  method46. Utilizing the  2−ΔΔCt method, results are presented 
as the fold change of gene normalized to the rpoB1 reference gene and relative to the control mice. The number 
of rpoB1 housekeeping gene for the determinaton of the K. pneumoniae relative amount in the feces, and the 
blaCTX-M-15 and blaOXA-162 genes for determining the relative amount of resistance genes compared to KP5825 
were determined on the first and on the fifteenth days.
Statistical analysis. Statistical analysis were performed using SSPS version 17.0 software (SPSS Inc., Chi-
cago, IL, USA) and Microsoft Office Excel 2007 (Microsoft, Redmond, WA, USA). The variables such as the copy 
number of the rpoB housekeeping gene, blaCTX-M-15 and blaOXA-161 genes were compared by Wilcoxon rank-sum 
Table 2.  Oligonucleotide probes and primers used in qPCR assays.
Oligonucleotides Sequences
rpoB1 forward primer 5′ CCC ACT ACG GTC GCG TAT G 3’
rpoB1 reverse primer 5′ CAG ACC GAT GTT CGG ACC TT 3’
rpoB1 probe 5′ VIC-CCG ATC GAA ACG CCT-MGB 3’
oxa-162 forward primer 5′ GGG CGA ACC AAG CAT TTT T 3’
oxa-162 reverse primer 5′ GCG ATC AAG CTA TTG GGA ATT T 3’
oxa-162 probe 5′ FAM-CCC GCA TCT ACC TTT-MGB-NFQ 3’
ctx-m-15 forward primer 5′ CGA CGT TAA ACA CCG CCA TT 3’
ctx-m-15 reverse primer 5′ TGC CCG AGG TGA AGT GGT A 3’
ctx-m-15 probe 5′ FAM-CGG GCG ATC CGC GTG-MGB-NFQ 3’
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test. A p-value of less than 0.05 was considered statistically significant. P-values are represented by arterisks (*, 
p < 0.05; **, p < 0.001; ***, p < 0.0001).
Ethics approval. Animals were maintained and handled in accordance with the recommendations of the 
Guidelines for the Care and Use of Laboratory Animals and the experiments were approved by the Animal Care 
Committee of Semmelweis University (Permission No. PE/EA/60-8/2018, PE/EA/964-5/2018).
Consent to participate. Not applicable.
Data availability
The dataset supporting the conclusions of this article is included within the article.
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